Personalized glycemic response led digital therapeutics program improves time in range in a period of 14 days

Verma, Ritika; Bhardwaj, Shefali; Lathia, Tejal; Kalra, Sanjay; Ranadive, Ruchira; Tanna, Snehal; Padsalge, Mahesh; Juneja, Archana; Samundra, Kirti; Thakkar, Piya Ballani; Jain, Vandana; Kini, Vishal; Kothari, Sneha; Guntur, Saimala; Joshi, Shilpa; Singal, Arbinder

doi:10.1007/s13410-022-01111-1

Cited by 4 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In week 2, the mean blood glucose level was significantly reduced by 17.5 mg/dL ( P <.001) and the time in range (TIR) and the glucose management indicator significantly improved by 4.5% and 0.4%, respectively ( P <.001), while the time above range (TAR) reduced significantly by 11% ( P <.001). The changes in the CGM metrics in that study indicated that the Fitterfly Diabetes CGM program significantly improved glycemic control in a short duration [ 23 ]. However, the extent of improvement in glycemic control after the completion of the program at 90 days was not studied.…”

Section: Introductionmentioning

confidence: 99%

Fitterfly Diabetes CGM Digital Therapeutics Program for Glycemic Control and Weight Management in People With Type 2 Diabetes Mellitus: Real-world Effectiveness Evaluation

Joshi¹,

Verma²,

Lathia³

et al. 2023

JMIR Diabetes

Self Cite

View full text Add to dashboard Cite

Background Digital therapeutic platforms facilitate health care through patient-centered strategies based on multidisciplinary teams and shared decision-making. Such platforms can be used for developing a dynamic model of diabetes care delivery, which can help in improving glycemic control by promoting long-term behavior changes in people with diabetes. Objective This study aims to evaluate the real-world effectiveness of the Fitterfly Diabetes CGM digital therapeutics program for improving glycemic control in people with type 2 diabetes mellitus (T2DM) after the completion of 90 days in the program. Methods We analyzed deidentified data of 109 participants in the Fitterfly Diabetes CGM program. This program was delivered through the Fitterfly mobile app coupled with continuous glucose monitoring (CGM) technology. This program consists of 3 phases: the first phase is observation, wherein the patient’s CGM readings are observed for 7 days (week 1); the second phase is the intervention; and the third phase aims at sustaining the lifestyle modification introduced during the second phase. The primary outcome of our study was the change in the participants’ hemoglobin A1c (HbA1c) levels after program completion. We also evaluated the changes in participant weight and BMI after the program, changes in the CGM metrics in the initial 2 weeks of the program, and the effects of participant engagement in the program on improving their clinical outcomes. Results At the end of the 90 days of the program, the mean HbA1c levels, weight, and BMI of the participants were significantly reduced by 1.2% (SD 1.6%), 2.05 (SD 2.84) kg, and 0.74 (SD 1.02) kg/m2 from baseline values of 8.4% (SD 1.7%), 74.45 (SD 14.96) kg, and 27.44 (SD 4.69) kg/m2 in week 1, respectively (P<.001). The average blood glucose levels and time above range values showed a significant mean reduction by 16.44 (SD 32.05) mg/dL and 8.7% (SD 17.1%) in week 2 from week 1 baseline values of 152.90 (SD 51.63) mg/dL and 36.7% (SD 28.4%), respectively (P<.001 for both). Time in range values significantly improved by 7.1% (SD 16.7%) from a baseline value of 57.5% (SD 25%) in week 1 (P<.001). Of all the participants, 46.9% (50/109) showed HbA1c reduction ≥1% and 38.5% (42/109) showed weight loss ≥4%. The average number of times the mobile app was opened by each participant during the program was 108.80 (SD 127.91) times. Conclusions Our study shows that participants in the Fitterfly Diabetes CGM program showed a significant improvement in their glycemic control and reduction in weight and BMI. They also showed a high level of engagement with the program. Weight reduction was significantly associated with higher participant engagement with the program. Thus, this digital therapeutic program can be considered as an effective tool for improving glycemic control in people with T2DM.

show abstract

Section: Introductionmentioning

confidence: 99%

Fitterfly Diabetes CGM Digital Therapeutics Program for Glycemic Control and Weight Management in People With Type 2 Diabetes Mellitus: Real-world Effectiveness Evaluation

Joshi¹,

Verma²,

Lathia³

et al. 2023

JMIR Diabetes

Self Cite

View full text Add to dashboard Cite

show abstract

“…Digital therapeutics (DTx) is one such technology for the prevention and personalized management of DM based on evidence-based therapeutic interventions delivered through mobile applications and remote health coaching by healthcare professionals from different specialties. [ 3 ]…”

Section: Introductionmentioning

confidence: 99%

Digital therapeutics in diabetes: A significant tool to address employees' health and productivity

Singal¹,

Thirumalai²

2022

Indian J Occup Environ Med

View full text Add to dashboard Cite

Emerging health care technologies in diabetes: is it the way forward?

Chawla¹

2023

Int J Diabetes Dev Ctries

View full text Add to dashboard Cite

Personalized glycemic response led digital therapeutics program improves time in range in a period of 14 days

Cited by 4 publications

References 28 publications

Fitterfly Diabetes CGM Digital Therapeutics Program for Glycemic Control and Weight Management in People With Type 2 Diabetes Mellitus: Real-world Effectiveness Evaluation

Fitterfly Diabetes CGM Digital Therapeutics Program for Glycemic Control and Weight Management in People With Type 2 Diabetes Mellitus: Real-world Effectiveness Evaluation

Digital therapeutics in diabetes: A significant tool to address employees' health and productivity

Emerging health care technologies in diabetes: is it the way forward?

Contact Info

Product

Resources

About